Objectives To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6,
CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a …

Background Previous studies suggested that polymorphisms in the CYP2B6 gene (which
encodes an isoenzyme that metabolizes bupropion) and in the ANKK1 gene (which is …

Objectives CYP2A6 is the major enzyme involved in nicotine metabolism, yet large
interindividual variations in the rate of nicotine metabolism exist within groups of individuals …

Polymorphisms of CYP450 metabolizer enzymes and transport proteins play crucial roles in
the inter‐individual variability of drug efficiency. The aim of our study was to predict the …

The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic
nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for …

Tobacco smoking continues to be the largest preventable cause of premature morbidity and
mortality throughout the world, including chronic respiratory diseases such as asthma and …

The extensively polymorphic CYP2B6 gene metabolizes endogenous and exogenous
compounds, among which are nicotine and bupropion, although its contribution to the …

Differences in metabolism of drugs can lead to severe toxicity or therapeutic failure. In
addition to cytochrome P450 2D6, which plays a critical role in drug metabolism, ABCB1 …

Background There is a high interindividual variability in cytochrome P4501A2 (CYP1A2)
activity and in its inducibility by smoking, only poorly explained by known CYP1A2 …

Background Even though bupropion is first-line pharmacological agent for smoking
cessation, not all the smokers successfully quit smoking by bupropion. It means other factors …